Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
Related news for (PRAX)
- Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
- Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
- Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
- Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome